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Dear Editor,
We read with interest the recent review by Granito 
and Bolondi published in your journal.
1
We appreciate in particular the consideration of the 
emerging role of metabolic syndrome as an importa
risk  factor  for  hepatocellular  carcinoma  (HCC) 
development,  and  we  describe  a  case  of  HCC 
developing in an African women without cirrhosis who 
achieved  sustained viral response (SVR) after antiviral 
treatment  for  HCV-related  chronic  hepatitis.  In  this 
patient  the  main  known  risk  factors  for  HCC 
development (high-grade  fibrosis,    overt/occult  HBV 
infection, alcohol use, advanced age and male gender) 
were absent, and the only risk factor was diabetes.
Case description.
In  march  2006,  T.A.,  a  55-years
woman, was diagnosed with  HCV-correlated chronic 
hepatitis,  genotype  1b,  high  viral  load  (quantitative 
HCV-RNA  >  5,500,000  UI/ml)  and  slight  serum 
aminotransferases  increase  (alanine  aminotransferase 
(ALT)  46,  aspartate  aminotransferase  (AST)  44; 
normal values: 6-31 IU/ml).
Liver ultrasound did not reveal neither focal echo
structural alterations, nor signs of portal hypertension 
and cirrhosis.
HCV  infection  duration  was  unknown  and  the 
patient  was  drug-naïve.  The  patient  denied drug and 
alcohol  use,  blood  transfusions  and  did  not  have 
piercings  and  tattoos.  She  was  affected  by  diabetes 
mellitus  type  2,  and  was  under  treatment  with  oral 
hypoglycemic  drugs  with  good  metabolic  control. 
Schistosomiasis  and  HBV  serology  were  negative, 
alpha-fetoprotein level was normal, and there were non 
contraindication  to  antiviral  treatment.  The  patient 
refused liver biopsy. 
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1
We appreciate in particular the consideration of the 
emerging role of metabolic syndrome as an important 
risk  factor  for  hepatocellular  carcinoma  (HCC) 
development,  and  we  describe  a  case  of  HCC 
developing in an African women without cirrhosis who 
achieved  sustained viral response (SVR) after antiviral 
related  chronic  hepatitis.  In  this 
patient  the  main  known  risk  factors  for  HCC 
grade  fibrosis,    overt/occult  HBV 
infection, alcohol use, advanced age and male gender) 
were absent, and the only risk factor was diabetes.
years-old  Ethiopian 
correlated chronic 
hepatitis,  genotype  1b,  high  viral  load  (quantitative 
RNA  >  5,500,000  UI/ml)  and  slight  serum 
aminotransferases  increase  (alanine  aminotransferase 
aspartate  aminotransferase  (AST)  44; 
Liver ultrasound did not reveal neither focal echo-
structural alterations, nor signs of portal hypertension 
HCV  infection  duration  was  unknown  and  the 
he  patient  denied drug and 
alcohol  use,  blood  transfusions  and  did  not  have 
piercings  and  tattoos.  She  was  affected  by  diabetes 
mellitus  type  2,  and  was  under  treatment  with  oral 
hypoglycemic  drugs  with  good  metabolic  control. 
ogy  were  negative, 
fetoprotein level was normal, and there were non 
contraindication  to  antiviral  treatment.  The  patient 
Therefore,  treatment  with  peg
mcg SC once weekly plus Ribavirin (RBV) 1000 mg/d 
PO  was  initiated.  Rapid  virological  response  (RVR) 
was not obtained at fourth week, but she reached early 
virological  response  (EVR)  at  week  12,  and  she 
successfully  completed  the  scheduled  48  weeks 
treatment protocol. End of treatment response (ETR) 
was  obtained  at  week  48,  and  sustained  virological 
response  (SVR)  confirmed  at  week  24  follow  up 
control visit (April 2008).
The  patient  did  not  attend  further  outpatient  visit 
until January 2010, when ultrasound scan showed a 5
cm-diameter  focal  lesion  suspicious  for  h
neoplasia.  Abdominal  CT  scan  confirmed  the  solid 
lesion  (liver  segments  VIII  and  VII),  which  showed 
marked and early enhancement after contrast medium 
infusion,  with  peripheral  ring  and  hyperdense  star
shaped nucleus, dimension 5 x 4.5 cm, with asso
altered  vascularisation  in  the  parenchymal  area.  The 
clinical report required liver biopsy to differentia the 
between focal nodular hyperplasia (FNH) and HCC.
On January 22
nd, 2010, liver biopsy was performed 
and  histological  report  described  slight
hepatitis  (G2  F1  according  to  Ishak  score),  and 
evidence  of  trabecular  neoplasia  with  positive 
immunohistochemical  markers  consistent  with  the 
diagnosis of HCC. 
Immunohistochemical staining for hepatitis B virus 
antigen  (HBsAg)  and  core  antigen  (
negative.
On February 23
rd, 2010, the patient firs underwent 
arterial  chemoembolisation  (lipiodol  plus 
farmorubicin)  of  the  HCC  and  later  portal 
chemoembolisation.
On  April  1
st,  2010,  follow  up  CT  scan  showed 
compensatory  hypertrophy  of  the  le
successful  chemoembolization  outcomes,  with 
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mcg SC once weekly plus Ribavirin (RBV) 1000 mg/d 
itiated.  Rapid  virological  response  (RVR) 
was not obtained at fourth week, but she reached early 
virological  response  (EVR)  at  week  12,  and  she 
successfully  completed  the  scheduled  48  weeks 
treatment protocol. End of treatment response (ETR) 
t  week  48,  and  sustained  virological 
response  (SVR)  confirmed  at  week  24  follow  up 
The  patient  did  not  attend  further  outpatient  visit 
until January 2010, when ultrasound scan showed a 5-
diameter  focal  lesion  suspicious  for  hepatic 
neoplasia.  Abdominal  CT  scan  confirmed  the  solid 
lesion  (liver  segments  VIII  and  VII),  which  showed 
marked and early enhancement after contrast medium 
infusion,  with  peripheral  ring  and  hyperdense  star-
shaped nucleus, dimension 5 x 4.5 cm, with associated 
altered  vascularisation  in  the  parenchymal  area.  The 
clinical report required liver biopsy to differentia the 
between focal nodular hyperplasia (FNH) and HCC.
, 2010, liver biopsy was performed 
and  histological  report  described  slight chronic 
hepatitis  (G2  F1  according  to  Ishak  score),  and 
evidence  of  trabecular  neoplasia  with  positive 
immunohistochemical  markers  consistent  with  the 
Immunohistochemical staining for hepatitis B virus 
antigen  (HBsAg)  and  core  antigen  (HBcAg)  were 
, 2010, the patient firs underwent 
arterial  chemoembolisation  (lipiodol  plus 
farmorubicin)  of  the  HCC  and  later  portal 
,  2010,  follow  up  CT  scan  showed 
compensatory  hypertrophy  of  the  left  liver  lobe  and 
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hypodense  areas  near  the  main  lesion  attributable to 
necrosis  of  the  hepatic tissue  adjacent  to  the  treated 
neoplasia.
On  April  23
rd,  2010,  right  hepatectomy  was 
performed.  Histological  examination  of  the  surgical 
sample showed poorly differentiated liver cancer with 
pleomorphic  cytological  features  (G3)  in  the 
framework  of  slight  chronic  hepatitis  with  extensive 
necrotic areas. The neoplasm did not infiltrate resection 
margin. Post-operative course was uneventful.
In  June  2010,  abdominal  CT  scan  showed  right 
hepatectomy  outcomes  with  regularly-bordered 
residual liver, without diffuse or focal alterations of the 
liver.
In October 2010, ultrasound scan evidenced further 
compensatory hypertrophy of the left lobe and no focal 
lesion.
Abdominal nuclear magnetic resonance performed 
in January 2011 was negative for focal lesions.
Discussion.
Some  similar  cases  describing  the  occurrence  of 
HCC in patients with chronic hepatitis C and SVR after 
interferon therapy have been reported in the literature.
2-
8 Makijama  et  al.
9 demonstrated that risk factors for 
developing  HCC  in  sustained  responders  after 
interferon  therapy  were:  advanced  age,  male  gender 
and more advanced histologic disease stage. 
Iwasaki  et  al.
10 observed  that  in  patients  with 
sustained  viral  response  to  interferon  treatment,  the 
main risk factors for HCC were the stage of fibrosis, 
age and alcohol abuse.
Another  study
11 on  1056  sustained  responders 
showed  that  older  age,  higher  serum AST  level  and 
lower  platelet  count  before  interferon  therapy  were 
independent  risk  factors  associated  with  the 
development of HCC.
Ikeda et al.
12 showed that in patients with chronic 
HCV  infection  responders  to  interferon  therapy,  an 
important  risk  factor for  liver  cancer  was  the 
concomitant presence of occult HBV infection.
Our case differs from those we have summarized 
since our patient did not have recognized risk factors: 
she was female, not old, with low-grade liver fibrosis, 
no alcohol consumption, low serum AST levels <100 
mg/dl,  normal  platelet  count  and  no  overt  or  occult  
HBV co-infection.
A  primary point to be discussed is the pathogenesis 
of HCC. It is well known that most HCCs develop in 
cirrhotic  liver,  but  in  15-20%  of  cases  it  can  also 
develop  in  non-cirrhotic  liver.
13 Therefore,  our 
observation  supports  the  notion  that  HCC  may  also 
develop in patients with chronic hepatitis C with mild 
fibrosis, as it happens in the case of HBV infection, 
where cirrhosis does not represent a pre-requisite for 
neoplasm formation.
HCC risk factors, besides HBV and HCV infection, 
include  alcohol  abuse,  ingestion  of  genotoxic 
substances such as aflatoxins, smoking, metabolic and 
congenital  disorders,  sexual  hormones  therapy,  iron 
overload,  family  case  history  of  liver  neoplasm  and 
diabetes.
13-16
In  the  case  we  have  presented,  apart  from  HCV 
infection,  the  only  possible  risks  factors  were 
aflatoxins exposition, which is frequent in Africa and 
Asia
15 and diabetes.
16
In particular, in the study of Hung et al,
16 type 2 
diabetes was an independent predictor of HCC in the 
subgroup  of  patients  without  cirrhosis  who  achieved 
SVR,  and  this  finding  is  consistent  with  two  other 
recent studies.
17-18 
Further  studies  are  needed  to  better  clarify  the 
pathogenic  mechanism  of  hepatocarcinogenesis  in 
diabetic patients without cirrhosis after eradication of 
HCV.
Conclusion.
It  has  recently  been  demonstrated  that  also  non-
cirrhotic patients affected by chronic hepatitis C with 
SVR after antiviral therapy may be at risk for HCC, 
even  if  they  show  very mild  fibrosis,  and  also  after 
many years from SVR.
13
In  addition,  our  case  confirm  the  need  for  a 
prolonged surveillance of non-cirrhotic patients even if 
they  are  sustained  responders  to  antiviral  therapy, 
although  the exact incidence of HCC in these subjects 
is still unknown.
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